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ResponseAbstract Background: Chronic hepatitis C virus (HCV) represents one of the common causes of
chronic liver disease worldwide with Egypt having the highest prevalence, namely genotype 4. The
rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphisms is associated with high
rates of sustained virological response to pegylated interferon and ribavirin in HCV genotype-1
patients. Data on other genotypes are more limited.
Objective: We aim to evaluate the predictive power of the rs12979860 IL28B single nucleotide poly-
morphisms for treatment response at 3 and 6 months in chronic HCV genotype 4 Egyptian patients
in relation to other predictors.
Patients and methods: The study included 60 chronic HCV Egyptian patients receiving pegylated
interferon and ribavirin therapy. Patients were classiﬁed into 2 groups; 30 patients with compen-
sated cirrhosis, and 30 patients without cirrhosis. We analyzed selected pretreatment factors such
as age, sex, HCV viral load, anti-schistosomal antibodies, insulin resistance, alpha fetoprotein,
low and high density lipoproteins and single nucleotide polymorphisms of IL28B and tried to ﬁnd
out which of them inﬂuence sustained virological response.
Results: In univariate analysis, CC genotype showed a signiﬁcant association with sustained
virological response at 6 months among the cirrhotic patients (81.8% responders had the CC
genotype, 58.3% had the CT/TT genotype) (p= 0.009). While in multivariate analysis, the presence
232 A.Y. Shaala et al.of cirrhosis showed higher risk of failed response at 3 and 6 months (p= 0.016 and 0.020 respec-
tively). Also, positive schistosoma serology was an important negative predictor of response at 3
and 6 months in both groups (p= 0.003 and 0.001 respectively).
Conclusion: In Egypt, where chronic HCV genotype 4 and schistosoma coinfection predominate,
both schistosoma infection and cirrhosis are more potent than IL28B polymorphisms as strong
baseline negative predictors of hepatitis C treatment response.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Hepatitis C virus (HCV) infection is one of the main causes of
chronic liver disease worldwide. The long-term impact of HCV
infection is highly variable, from minimal changes to extensive
ﬁbrosis and cirrhosis with or without hepatocellular carcinoma
(HCC). The number of chronically infected persons worldwide
is estimated to be about 160 million, but most of them are una-
ware of their infection.1
In fact, Egypt has the largest epidemic of HCV in the world
with an overall serum positive prevalence of 14.7% as reported
by the Egyptian demographic health survey, with >90% of
cases having HCV genotype 4.2,3 Hepatitis C virus (HCV)
genotype 4 is the most frequent cause of chronic hepatitis C
in the Middle East, North Africa, and sub-Saharan Africa.4
It has been reported to be frequently associated with cirrhosis
and a poor response to interferon (IFN).5,6 Furthermore, epi-
demiological reports indicate that HCV genotype 4 is begin-
ning to spread from its native African and Middle Eastern
origins to countries of Southern Europe such as France, Italy
and Spain and in some foci in the United States, particularly
among intravenous drug users.7–9
Chronic hepatitis C proceeds toward cirrhosis over several
decades. On average, 10 to 20% of patients develop cirrhosis
over 20–30 years of infection.1 Until 2011, treatment with
pegylated interferon (PEG-IFN) and ribavirin (RBV) was the
standard of care (SOC) for all HCV genotypes, with HCV
clearance depending both on virus and host-related factors.10
It has been reported that treatment with conventional IFN
is less effective in patients with genotypes 1 and 4 than in
patients with genotypes 2 and 3.11 European Association for
the Study of the Liver recommended that liver disease severity
should be assessed prior to therapy. Identifying patients with
cirrhosis is of particular importance, as their prognosis, their
likelihood of response and the duration of therapy are altered.1
Currently the treatment of chronic hepatitis is inclined
toward individualized therapy, based on the knowledge of fac-
tors predicting response to treatment.12 All treatment-naı¨ve
patients with compensated disease due to HCV should be con-
sidered for therapy. The goal of therapy is to eradicate HCV
infection to prevent liver cirrhosis, HCC, and death. The end-
point of therapy is undetectable HCV RNA in a sensitive assay
(<15 IU/ml) 12 and 24 weeks after the end of treatment (i.e.
sustained virologic response SVR12 and SVR24). In patients
with cirrhosis, HCV eradication reduces the rate of decompen-
sation and will reduce, albeit not abolish the risk of HCC. In
these patients screening for HCC should be continued.1
Several independent genome-wide association studies
(GWAS) reported single nucleotide polymorphisms (SNPs)
rs12979860, located 3 kilobases upstream of the IL28B gene,encodes a type III IFN (IFN-3) is associated with more than
a 2-fold difference in the rate of SVR.6 CC genotype of IL-
28B is associated with a 2–3-fold increase in sustained virologic
response (SVR) compared to CT or TT genotype.13,14
The mechanism by which SNPs inﬂuence the outcome of
HCV infection and its treatment is not clear. It is suggested
that regulation of the promoter region of IL28B in antiviral
activity may also affect two other genes belonging to interferon
(IFN) k family encoded in this region.15 There are a few data
so far regarding the role of IL28B polymorphism in HCV-4
patients with respect to response to antiviral therapy or ﬁbrosis
progression.16 The use of these genetic markers may help us to
select patients who are more or less prone to respond to pegy-
lated interferon plus ribavirin.
2. Aim of the work
This study assessed the predictive power of rs12979860 IL-28B
variations on the response to PEG-IFN/RBV therapy in a
group of Egyptian patients infected with chronic hepatitis C
(CHC) genotype 4 with and without cirrhosis, in relation to
other predictors of response.
3. Patients and methods
3.1. Ethical aspects
The study was approved by the local ethics committee of Alex-
andria University. All patients provided written informed con-
sent to participate in this study.
3.2. Patients and clinical data
Chronic infection was deﬁned as a detectable HCV RNA for at
least 6 months.17 The current study included 60 patients with
chronic HCV infection classiﬁed according to liver biopsy
and laboratory parameters into 2 groups: 30 patients with
chronic HCV and compensated cirrhosis, and 30 chronic
HCV infected patients without cirrhosis. All patients under-
went treatment under a standard protocol with PEG-IFN
and weight-based ribavirin (RBV) for 48 weeks. Patients were
recruited from the Tropical department of Alexandria Main
University Hospital.
Patients were subjected to thorough history taking, clinical
examination and routine pre-treatment work up. The baseline
HCV RNA load and subsequent viral concentrations in
response to treatment were measured using a quantitative
polymerase chain reaction (PCR) assay according to the avail-
able technique (Applied Biosystem, USA), with a detection
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the INNO-LiPA v2.0 (Innogenetics, Zwijndrecht, Belgium)
HCV assay.
Histopathological examination of histological activity and
degree of hepatic ﬁbrosis, of ultrasound guided percutaneous
liver biopsy, was performed according to the Metavir
score.18 The exclusion criteria included any cause of liver
disease other than chronic HCV based on the patient his-
tory, laboratory or liver biopsy ﬁndings as: HBV/HIV coin-
fection, autoimmune hepatitis, hemochromatosis, Wilson’s
disease, Alpha 1-antitrypsin deﬁciency, alcoholic liver dis-
ease, drug induced liver disease, decompensated liver dis-
ease19 (Total serum bilirubin >1.5 g/dL; INR >1.5; serum
albumin <3.4; platelet count <75,000 mm) and evidence
of hepatic decompensation (hepatic encephalopathy or asci-
tes), hepatic tumors, pregnancy or breast feeding, advanced
ischemic heart disease and uncontrolled diabetes (Hb A1C
>8.5%).
The outcome variable in this study was sustained viro-
logic response, deﬁned as non detectable HCV RNA in
serum 24 weeks after the completion of HCV therapy
(SVR24). Sustained virologic response is deﬁned as non
detectable HCV RNA in serum 12 weeks after the comple-
tion of HCV therapy (SVR12).1 Patients with detectable
plasma HCV RNA at week 24, were considered to be non
responders.203.3. Determination of the IL28B genotype
Genomic DNA are isolated from 200 ll of blood using the
QIAamp DNA Blood Mini Kit (Qiagen) according to the
manufacturer’s protocol, and preserved at 70 C for genetic
determinations. SNPs near IL28B (marker rs12979860) were
genotyped using TAQMAN genotyping assay (Applied
Biosystems). Primer and probe sequences were: Forward
Primer 5.-GCCTGTCGTGTACTGAACCA, Reverse Primer
5.-GCGCGGAGTGCAATTCAAC, Probe (C allele) 5.-VIC-
TGGTTCGCGCCTTC, Probe (T allele) 5.-FAM-CTGGTT
CACGCCTTC. Genotyping was performed in 25 ll reaction
volume containing 10 ng DNA, 12.5.l TaqMan Universal
PCR Master Mix and 1.25.l (40·) Custom SNP Genotyping
Assays.3.4. Statistical analysis
Data were analyzed using SPSS version 16.0, the 0.05 level was
used as the cut off value for statistical signiﬁcance. Counts and
percentage were used for describing and summarizing qualita-
tive data, the arithmetic mean (X) and the standard deviation
(SD) were used as measures of central tendency and dispersion
respectively for normally distributed quantitative data. The
association between two qualitative variables was done using
Chi square test (v2) and Fisher Exact test (FET), and Monte
Carlo Exact probability (MCP) was used when v2 is not valid
(>20% of the expected cells have count less than 5),
Mann–whitney Z test was done for comparing two indepen-
dent quantitative non-normally distributed variables. A
stepwise logistic regression model to extract the most
signiﬁcant factors contributing in the response of the patient
in 3 and 6 months was done.4. Results
4.1. Features of the study population
The study group consisted of 60 chronic HCV infected
patients, out of whom 30 were cirrhotic. Clinical and demo-
graphic characteristics of the patients enrolled in this study
are summarized in Table 1. All patients were infected with
HCV genotype 4 and were on anti-viral therapy. These charac-
teristics were comparable in the 2 groups with no statistical sig-
niﬁcance except for the mean age which was slightly higher
among the HCV group as compared to the group of HCV
combined with cirrhosis, this difference although very small
showed to be signiﬁcant. The AST showed a signiﬁcantly
higher mean among the chronic HCV and cirrhosis group as
compared to the other group. Schistosomal serology showed
signiﬁcant association, denoting a more frequent schistosoma
infection among chronic HCV cirrhotic patients. All other
studied lab parameters showed some difference but yet not sta-
tistically signiﬁcant. The genotype frequency of rs12979860 CT
was the most common (56.7%), occurring more frequently in
non-cirrhotic patients (60%), than in chronic HCV with the
cirrhosis group. This was statistically non signiﬁcant.
4.2. Outcome of antiviral therapy (Table 1)
Cirrhotic patients achieved signiﬁcantly lower SVR12 and
SVR24 rates than non cirrhotics (12/30 = 40% and 14/
30 = 46.7%) versus (23/30 = 76.7% and 24/30 = 80%)
(p= 0.004 and 0.007) respectively.
4.3. Baseline predictors of treatment outcome
4.3.1. SVR12
Higher BMI was signiﬁcantly associated with failure of
response among the non cirrhotic group, when compared to
responders (30.7 ± 1.9 and 27.7 ± 2.8 respectively)
(p= 0.015) while higher GGTP, INR, PT, AFP, insulin resis-
tance index (IR) and lower serum albumin levels, as well as a
higher rate of positive schistosomal serology, were signiﬁcantly
associated with failure of response in the cirrhotic group
(p< 0.05) (Table 2).
In the logistic regression model, we evaluated the odds ratio
(OR) and the 95% conﬁdence interval (CI) of SVR12, depend-
ing on the most signiﬁcant predictors of response after
3 months.
The OR revealed that cirrhotic patients had a 6.39 higher
risk of non response than non cirrhotic patients (p= 0.016).
Presence of schistosomal antibodies had nearly 12 times
greater probability of achieving non response compared with
negative schistosomal serology (p= 0.003). Also patients with
higher BMI had 19-fold higher chance more than non obese
(Normal and Overweight) to be non responders (p= 0.001)
(Table 3).
4.3.2. SVR24
In the non cirrhotic group, higher mean of cholesterol and
LDL levels, lower mean INR, PT and negative serology for
schistosomiasis demonstrated a signiﬁcant association with
response.
Table 1 Demographic and biochemical features of patients included in this study.
Parameter Group Test of signiﬁcance (p Value)
Chronic HCV+ cirrhosis (n= 30) Chronic HCV (n= 30)
Age (years) 45.3 ± 7.7 49 ± 7.7 Z= 2.01 (0.045)
Female (N/%) (17/28.3) 8 (26.7) 9 (30) X2 = 0.08
Male (N/%) (43/71.7) 22 (73.3) 21 (70) p= 0.774
BMI (kg/m2) 28 ± 3.1 28.4 ± 2.9 Z= 0.75 (0.451)
AST(IU/L) 53 ± 23.7 47.3 ± 38.6 Z= 2.20 (0.028)
Alb (g/dl) 3.4 ± 0.4 4.1 ± 0.53 Z= 1.19 (0.233)
GGTP (IU/L) 60.6 ± 47.3 72.8 ± 92.5 Z= 0.34 (0.734)
TLC count (·103/mm3) 4.50 ± 1.43 4.89 ± 1.61 Z= 0.98 (0.328)
Hb (g/dl) 12.7 ± 1.3 12.7 ± 1.6 Z= 0.26 (0.796)
Platelets (·103/mm3) 179.8 ± 63 183.5 ± 60.1 Z= 0.18 (0.859)
INR 1.1 ± 0.1 1.1 ± 0.0 Z= 1.61 (0.107)
PT 13.06 ± 1.37 12.29 ± 0.41 Z= 1.82 (0.069)
PCR-HCV (·106 IU/ml) 1.3 ± 1.4 1.8 ± 3.4 Z= 0.03 (0.976)
AFP(ng/ml) 9.1 ± 22.1 10.6 ± 22.2 Z= 0.26 (0.796)
Schistosomal serology (N/%)
Negative (43/71.7) 17 (56.7) 26 (86.7) X2 = 6.65
Positive (17/28.3) 13 (43.3) 4 (13.3) p= 0.010
Cholesterol (mg/dl) 149.4 ± 38.9 151.6 ± 30.6 Z= 0.40 (0.690)
HDL (mg/dl) 48.2 ± 18.2 53.9 ± 18.8 Z= 1.37 (0.171)
LDL (mg/dl) 78.9 ± 27.0 75.9 ± 29.8 Z= 0.53 (0.600)
IR 4.8 ± 10.2 2.4 ± 1.4 Z= 0.27 (0.784)
IL28B genotypes (N/%)
CC (18/30) 11 (36.7) 7 (23.3) MCp = 0.471
CT (34/56.7) 16 (53.3) 18 (60)
TT (8/13.3) 3 (10) 5 (16.7)
SVR12 (N/%)
Responders (35/58.3) 12 (40) 23 (76.7) X2 = 8.5
Non responders (25/41.7) 18 (60) 7 (23.3) p= 0.004
SVR24 (N/%)
Responders (38/63.3) 14 (46.7) 24 (80) X2 = 7.18
Non responders (22/36.7) 16 (53.3) 6 (20) p= 0.007
Note: BMI: body mass index, (calculated as the square of height in meters divided by weight in kilograms), AST: aspartate aminotransferase,
Alb: albumin, GGTP: gamma-glutamyl transpeptidase, TLC: total leukocytic count, Hb: hemoglobin, PT: prothrombin time, AFP: alpha
fetoprotein, HDL: high-density lipoprotein, LDL: low-density lipoprotein, IR: insulin resistance, SVR12: sustained virologic response 12 weeks
after the completion of HCV, SVR24: sustained virologic response 24 weeks after the completion of HCV therapy. Data are presented as
mean ± SD unless otherwise indicated.
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showed a higher mean among non responders than responders
and this was shown to be signiﬁcant. The higher mean of
HDL, negative schistosomal serology and CC IL28 B genotype
showed a signiﬁcant association with SVR24. Nine responders
(81.8%) had the CC genotype, and 5 (58.3%) had the CT/TT
genotype (p= 0.009) (Table 4).
As for the OR and the 95% CI of SVR24 after 6 months,
positive schistosomal serology is the strongest predictor of
non response, being more potent (p= 0.001) than the presence
of cirrhosis (p= 0.020) and IL28B genotype (Table 5).5. Discussion
This study was undertaken to assess the predictive power of
rs12979860 IL-28B variations on the response to PEG-IFN-./
RBV therapy in a group of Egyptian patients infected with
chronic HCV genotype 4 with and without compensated cir-
rhosis, in relation to other predictors of response.There are many pretreatment factors such as age, sex, eth-
nicity, body mass index, insulin resistance, hepatic steatosis,
and degree of liver ﬁbrosis, HCV genotype, baseline viral load
and viral kinetics during treatment which can inﬂuence the
response to the therapy with Peg-IFN and ribavirin.12
Our ﬁndings showed that the higher mean age and the pres-
ence of negative schistosomal serology were statistically signif-
icant in the non-cirrhotic group (p= 0.045, p= 0.010
respectively), denoting a more frequent schistosoma infection
among chronic HCV cirrhotic patients. Kamal et al. 21
reported that HCV/schistosomiasis coinfected patients have
more rapid progression of hepatic ﬁbrosis than those with
HCV monoinfection.
Base line AST level was signiﬁcantly lower in the non-cir-
rhotic group (p= 0.028), as reported by Al Ashgar et al.22
who demonstrated that the AST reﬂects less severe histopa-
thological parameters.
Recent genome-wide association studies (GWAS) have
shown that human genetic variations (single-nucleotide
polymorphisms, SNPs) around the gene for interleukin 28B
Table 2 Relationship between SVR12 and demographic and biochemical variables among both studied groups.
Parameter Chronic HCV with cirrhosis p-Value Chronic HCV without cirrhosis p-Value
Responders
(n= 12)
Non-responders
(n= 18)
Responders
(n= 23)
Non-responders
(n= 7)
Age (years) 43.1 ± 9.8 46.8 ± 5.8 0.106 48.4 ± 7.5 51.0 ± 8.5 0.446
BMI (kg/m2) 27.2 ± 2.3 28.6 ± 3.6 0.363 27.7 ± 2.8 30.7 ± 1.9 0.015
Alb (g/dl) 4.2 ± 0.3 3.8 ± 0.4 0.018 4.1 ± 0.5 3.9 ± 0.7 0.507
GGTP (IU/L) 40.3 ± 29.0 74.2 ± 52.8 0.026 3.7 ± 96.9 67.0 ± 83.1 0.624
AST (IU/L) 51.9 ± 25.3 53.7 ± 23.3 0.932 51.2 ± 43.1 34.4 ± 11.6 0.508
TLC (·103/mm3) 4.3 ± 1.1 4.6 ± 1.6 0.671 5.1 ± 1.5 4.2 ± 2.0 0.141
Hb (g/dl) 12.9 ± 1.5 12.5 ± 1.2 0.351 12.8 ± 1.7 12.3 ± 1.0 0.572
Platelets (·103/mm3) 176.5 ± 54.7 181.9 ± 69.4 0.816 185.9 ± 65.5 175.6 ± 40.6 0.961
INR 1.0 ± 0.1 1.1 ± 0.1 0.029 1.0 ± 0.0 1.0 ± 0.0 0.499
PT 12.5 ± 0.8 13.5 ± 1.5 0.020 12.3 ± 0.4 12.2 ± 0.4 0.587
PCR-HCV (·106 IU/ml) 1722030.9 ±
1114642.4
1089318.8 ±
1480267.6
0.057 1112806.3 ±
1067043.9
4184974.9 ±
6605613.9
0.249
AFP (ng/ml) (mean ± SD) 4.1 ± 5.1 12.4 ± 28.1 0.028 8.0 ± 12.3 19.2 ± 41.4 0.731
Cholesterol (mg/dl) 152.3 ± 32.5 147.6 ± 43.4 0.687 154.3 ± 29.6 142.4 ± 34.4 0.364
HDL (mg/dl) 57.4 ± 23.1 42.0 ± 11.0 0.094 54.1 ± 20.8 53.3 ± 11.6 0.864
LDL (mg/dl) 73.8 ± 16.8 82.3 ± 32.1 0.485 79.2 ± 30.2 64.9 ± 28.0 0.229
IR 1.6 ± 0.7 6.9 ± 12.9 0.034 2.4 ± 1.4 2.3 ± 1.4 0.922
Male (N/%) 8 (36.4) 14 (63.6) FETp = 0.678 15 (71.4) 6 (28.6) FETp = 0.393
Female (N/%) 4 (50.0) 4 (50.0) 8 (88.9) 1 (11.1)
Schistosomal serology (N/%)
Negative 10 (58.8) 7 (41.2) FET p = 0016. 20 (76.9) 6 (23.1) FETp = 0.999
Positive 2 (15.4) 11 (84.6) 3 (75.0) 1 (25.0)
IL28B (N/%)
CC 6 (54.5) 5 (45.5) MCP= 0.267 5 (71.4) 2 (28.6) MCP= 0.591
CT 6 (37.5) 10 (62.5) 13 (72.2) 5 (27.8)
TT 0 (0.0) 3 (100) 5 (100) 0 (0.0)
Data are presented as mean ± SD unless otherwise indicated.
Table 3 Odds ratio of SVR12 depending on the patient
group, BMI and schistosomal serology.
Factors aﬀecting SVR12 p value OR 95% CI
Cirrhotic group 0.016 6.39 1.41–28.87
BMI 0.001 19.07 3.15–115.66
Positive schistosomal serology 0.003 12.88 2.34–70.83
Model X2 = 26.57 p = 0.000
OR: odds ratio, CI: conﬁdence interval.
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of adults chronically infected with HCV and that they can be
useful as therapy response markers.17
The IL28B polymorphism rs12979860 has a marked differ-
ential distribution between racial groups, being least frequent
in African Americans, most frequent in Asians, and with an
intermediate frequency in Hispanics and Caucasians.23
This global difference of allele frequency might explain the
ethnic variations seen in the treatment response among these
populations.24
The frequency of IL28 genotype in our genotype 4 Egyptian
patients showed that almost half of them were of the CT geno-
type (56.7%) followed by CC (30%) while TT had the least
expression (13%). The CC genotype occurred more frequently
in cirrhotic patients compared to non cirrhotic patients (11/30vs. 7/30), unlike CT and TT genotypes that were more frequent
in chronic HCV patients compared to HCV with cirrhosis (18/
30 and 5/30 vs. 16/30 and 3/30 respectively), but this was sta-
tistically non signiﬁcant.
These results were matching with the study of Khairy et al.23
who reported that the frequency of IL28 genotype in their 263
chronic HCV patients genotype 4 Egyptian patients was 56%
for the CT genotype, followed by 25% for CC while TT had
the least expression (19%). De Nicola group (2012)25 which
included 128 patients with genotype 4, 68% Egyptians, showed
63% CT, 14% TT, and 23% CC expression. Also, Asselah and
colleagues26 studied 164 patients with genotype 4 (43% Egyp-
tians), and found the difference in distribution of IL 28 B
genotype between Egyptians and Subsaharan Africans; in the
Egyptian ethnicity the frequency was 55% CC, 11% TT and
34% CT, while in the in sub-Saharan group the TT genotype
was the most predominant form (48%). El-Awady and col-
leagues during 2012 also in a study on genotype 4, found that
the frequencies of genotypes were 48% CC, 14% TT, and 38%
CT for their studied patients.27
This was inconsistent with previous results describing a
higher incidence of TT or CT allele in cases of cirrhosis and
faster ﬁbrosis progression in HCV-infected liver transplant
recipients and liver from donors with the TT genotype,28,29
and that TT genotype occurred more frequently in patients
with end stage liver disease,23 as well as that of Ciesla et al.15,
who studied 64 Caucasian chronic HCV patients on IFN and
Table 5 Odds ratio of SVR24 depending on the patient
group, type of polymorphism of IL28B and schistosomal
serology.
Factors aﬀecting SVR24 p value OR 95% CI
Cirrhotic group 0.020 11.40 1.46–88.84
CT 0.043
CC 0.384 2.99 0.25–35.24
TT 0.064 0.03 0.00–1.22
Positive schistosomal serology 0.001 132.25 7.34–2383.52
Model X2 = 46.43 p= 0.000
OR: odds ratio, CI: conﬁdence interval.
Table 4 Relationship between SVR24 and demographic and biochemical variables among both studied groups.
Parameter Chronic HCV with cirrhosis p-Value Chronic HCV without cirrhosis p-Value
Responders
(n= 14)
Non-responders
(n= 16)
Responders
(n= 24)
Non-responders
(n= 6)
Age (years) 44.1 ± 9.0 46.4 ± 6.5 0.337 49.3 ± 7.6 48.0 ± 8.7 0.815
BMI (kg/m2) 28.2 ± 2.7 27.9 ± 3.6 0.506 28.8 ± 2.7 26.7 ± 3.3 0.186
Alb (g/dl) 4.1 ± 0.4 3.8 ± 0.4 0.132 4.1 ± 0.5 4.0 ± 0.6 0.406
GGTP (IU/L) 32.6 ± 17.6 85.2 ± 51.8 0.001 72.3 ± 102.2 71.7 ± 39.4 0.169
AST (IU/L) 53.1 ± 28.2 52.8 ± 19.9 0.901 50.0 ± 42.7 36.5 ± 8.2 0.917
TLC (·103/mm3) 4.6 ± 1.8 4.4 ± 1.1 0.917 4.7 ± 1.7 5.6 ± 1.4 0.213
Hb (g/dl) 12.4 ± 1.2 12.9±.4 0.454 12.8 ± 1.7 12.4 ± 1.3 0.604
Platelets (·103/mm3) 175.4 ± 52.2 183.6 ± 72.6 0.835 182.3 ± 58.8 188.3 ± 71.0 0.795
PT 12.4 ± 0.8 13.7 ± 1.5 0.001 12.2 ± 0.4 12.6 ± 0.5 0.036
INR 1.0 ± 0.1 1.1 ± 0.1 0.000 1.0 ± 0.0 1.1 ± 0.0 0.058
PCR-HCV (·106 IU/ml) 1801612.1 ±
1743753.6
940596.3 ±
763112.5
0.212 1977492.3 ±
3780153.0
1238258.8 ±
1115577.7
0.717
AFP (ng/ml) 3.3 ± 2.7 14.2 ± 29.7 0.010 5.6 ± 7.3 30.9 ± 44.7 0.062
Cholesterol (mg/dl) 158.1 ± 38.0 141.8 ± 39.2 0.339 158.1 ± 29.7 125.5 ± 18.7 0.022
HDL (mg/dl) 57.3 ± 21.8 40.2 ± 9.2 0.019 52.8 ± 20.6 58.3 ± 9.2 0.222
LDL (mg/dl) 75.9 ± 24.8 1.5 ± 29.4 0.708 81.2 ± 29.9 54.5 ± 19.3 0.038
IR 2.0 ± 1.4 7.2 ± 13.7 0.096 2.3 ± 1.4 2.5 ± 1.4 0.678
Male (N/%) 9 (40.9) 13 (59.1) FETp = 0.417 16 (76.2) 5 (23.8) FETp = 0.400
Female (N/%) 5 (62.5) 3 (37.5) 8 (88.9) 1 (11.1)
Schistosomal serology (N/%)
Negative 13 (76.5) 4 (23.5) FETp = 0.000 23 (88.5) 3 (11.5) FETp = 0.018
Positive 1 (7.7) 12 (92.3) 1 (25.0) 3 (75.0)
IL28B (N/%)
CC 9 (81.8) 2 (18.2) MCP= 0.009 7 (100.0) 0 (0.0) MCP= 0.372
CT 4 (25.0) 12 (75.0) 13 (72.2) 5 (27.8)
TT 1 (33.3) 2 (66.7) 4 (80.0) 1 (20.0)
Data are presented as mean ± SD unless otherwise indicated.
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more active state of necroinﬂammation in the histological
analysis, and borderline signiﬁcance of greater severity of
ﬁbrosis. Taking into consideration that the distribution of
IL28B genotypes among both studied groups in the present
study was not statistically signiﬁcant, it was not possible to
conﬁrm the impact of the genotype on the progress of CHC.
Endpoint of therapy is the SVR, deﬁned by undetectable
HCV RNA 24 weeks after the end of therapy, as assessed by
a sensitive molecular method with a lower limit of detection
<15 IU/ml (SVR24). Long-term follow-up studies have shown
that an SVR corresponds to a deﬁnitive cure of HCV infection
in more than 99% of cases.1 The validity of using undetectableHCV RNA at 12 weeks after the end of therapy (SVR12) has
been accepted by regulators in the US and Europe, given that
the concordance with SVR24 is 99%.30
Various studies from European and Middle Eastern coun-
tries showed that the SVR in genotype 4 for combination ther-
apy, pegylated interferon and ribavirin, ranges between 43%
and 70%.31,32
In the current study, SVR12 and SVR24 showed signiﬁcant
association with non cirrhotic patients (p= 0.004, p= 0.007
respectively) denoting higher response among the same group.
This was close to Aghemo et al. results,33 where 53% of 409
HCV cirrhotic patients achieving an SVR compared to 75% of
non cirrhotics, and Thompson et al. study,34 showing lower
SVR rates in IL28B CC patients with bridging ﬁbrosis and
cirrhosis.
Little is known about predictors of response within popula-
tions infected with genotype 4. In previous studies on genotype
4; age, pretreatment viral load, and stage of ﬁbrosis were con-
sidered as good predictive factors.35,36
The gene expression and the role of IL28B gene SNP
rs12979860 in response to treatment in genotype 4 were
recently studied by limited research with CC genotype of
higher response rate.25,26
Relationship between baseline parameters and virological
response in the current study showed that, higher base line
GGTP, INR, PT, AFP levels, higher IR index, lower albumin
level and positive schistosomal serology antibodies are signiﬁ-
cantly associated with unfavorable outcomes after 3 months
Role of IL-28B polymorphisms in virologic response 237(SVR12) in cirrhotic group, while lower BMI value was the
only signiﬁcant predictor of SVR12 in non cirrhotic group.
The role of insulin resistance in response to HCV therapy is
controversial,20 the correlation between insulin resistance and
higher BMI and response to antiviral therapy observed in
the present study is consistent with Ciesla et al. results.15
In this study, although CC patients are more prone than
patients with the T allele to achieve an SVR12 in cirrhotic
patients, this is not the case in HCV non cirrhotic patients,
where CT/TT alleles are more prone to achieve SVR12, but
this was statistically non signiﬁcant.
Concerning rates of SVR24 in our study, cirrhotic patients
(genotype CC) did achieve it more frequently as compared to
genotype CT/TT, which was statistically signiﬁcant
(p= 0.009), while in the non cirrhotic group, this difference
was statistically non signiﬁcant.
This was in harmony with Khairy et al.23 study, where the
CC genotype was signiﬁcantly correlated with SVR in compar-
ison to CT and TT. The response rates were 50%, 47.4% and
25% for genotype CC, CT, and TT respectively. Absence of C
allele (TT genotype) was associated with 75% failure of
response; either early failure, e.g. non response (54.5%), or late
failure, e.g. relapsers (20.5%). This is in agreement with previ-
ous studies reported on genotype 115,37,38 and studies con-
ducted on genotype 4.26,25
On the other hand, in the study of Ciesla et al.,15 60% of
patients with SVR had TT (8%) or CT (52%) genotypes,
which are not known factors associated with higher IFN
responsiveness. These values are similar to those described in
previous reports, where analysis of the differences in the course
of therapy in patients with the CT allele and a SVR revealed
higher baseline platelet and neutrophil levels. A low baseline
platelet count was signiﬁcantly associated with the need for
IFN dose reduction in the group without a SVR.39
In the present study, negative serology for schistosoma
antibodies was a common predictor of SVR24 in both groups
of patients. Besides, we found 2 independent prognostic factors
for SVR24 in cirrhotic patients: Lower INR and PT level and
higher cholesterol and LDL levels. As regards the non cirrhotic
group, higher HDL level was a predictor of SVR24, while
higher GGT, INR, PT and AFP levels were associated with
failure of response. Base line viral load and base line AST lev-
els were not predictors of SVR24 in both groups.
In the study of Abdel-Rahman et al.40 the EVR, virological
response at week 24, and SVR were signiﬁcantly higher in
patients with negative schistosomal serology. This ﬁnding
may be attributed to the fact that coinfected patients with a
down-regulated immune response to HCV leading to reduced
IFN., interleukin (IL)-4 and IL-10 secreted by HCV-speciﬁc
T cells.
In contrast to our study, the analysis presented by McCar-
thy et al.38 showed that lower viral load before treatment pre-
dicted higher SVR. This phenomenon was not conﬁrmed in
our study, possibly due to the small sample size. This result
has been afﬁrmed by Correia et al.41 emphasizing that the
baseline HCV RNA is trivial for SVR.
In the study of Khairy et al.23, lower base line AST but not
ALT was an independent predictor of SVR in patients with
chronic HCV genotype 4. This was in accordance with Al Ash-
gar et al. study22 which demonstrated that the AST reﬂects less
severe histopathological parameters in sustained responders.Concerning the plasma levels of LDL, in vitro studies have
shown that LDL may competitively inhibit the binding of
HCV to the LDL receptor, which functions as one of the cel-
lular receptors for HCV. This competitive blockade would
hamper the infection of hepatocytes with HCV. Accordingly,
higher levels of plasma LDL (as in the current results) have
been shown to be an independent predictor of SVR, in studies
speciﬁcally designed to appraise this issue.20
Higher serum AFP level was a strong negative predictor of
SVR24 in the studied patients. Previous studies including HCV
genotype 442,43 and genotype 144,45 highlighted the same ﬁnd-
ings. Abdoul et al.46 examined the association between serum
alpha-fetoprotein level and sustained SVR in 93 chronic hepa-
titis C patients and found that the SVR rate was much higher
among patients with serum AFP levels below rather than
above a median value of 5.7 ng/ml, denoting that serum
AFP should be added to the list of factors predictive of treat-
ment response in chronic hepatitis C.
The results of multivariate analysis in this study show that 3
factors only were considered to be signiﬁcant negative predic-
tors of response after 3 months (SVR12), which are presence of
cirrhosis, high BMI and positive schistosomal serology. As
regards SVR24 after 6 months, positive schistosomal serology
is the strongest predictor of non response, being more potent
than the presence of cirrhosis and IL28B genotype.
We can conclude that concomitant absence of cirrhosis and
negative serology for bilharzial infections do seem to improve
responses achieved with pegylated interferon plus ribavirin
combination therapy for HCV genotype 4. In Egypt, where
chronic HCV genotype 4 and schistosoma coinfection predom-
inate, both schistosoma infection and cirrhosis are more potent
than IL28B polymorphisms as strong baseline negative predic-
tors of hepatitis C treatment response.
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